Fund moves
5.0%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
QNRX · NASDAQ · Pharmaceutical Preparations
Quoin Pharmaceuticals (QNRX) · oqro.io/stocks/QNRX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Quoin Pharmaceuticals was filed in the last 90 days. The latest on record was on Dec 27, 2024.
Since 2024, Quoin Pharmaceuticals insiders reported 17 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 1 different year, most recently 2024.
No open-market sale by an insider of Quoin Pharmaceuticals (QNRX) was filed with the SEC in the last 90 days.
No trade in Quoin Pharmaceuticals (QNRX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$3.28−0.0791 (−2.35%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−82.2% (−$15.14) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $18.42 on Nov 20, 2025 to $3.28 on Nov 20, 2026 (−82.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Ashburn, Va.
Last 12 months
−82.2%
Market value
$236M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 24K shares sold short (0.0% of shares outstanding), +17.2% vs the previous count, 1.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $10.1M, at Sep 30, 2026
Net income, last 12 months
−$19.6M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 6, 2026.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider buying
Traded Dec 23, 2024 · filed 4 days later
Since the trade −82.0% · S&P 500 +16.0% · to Nov 20
The CEO of Quoin Pharmaceuticals paid $250K out of pocket for Quoin Pharmaceuticals shares. 3 other people at Quoin Pharmaceuticals bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Dec 23, 2024 · filed 4 days later
Since the trade −82.0% · S&P 500 +16.0% · to Nov 20
A Quoin Pharmaceuticals director paid $250K out of pocket for Quoin Pharmaceuticals shares. 3 other people at Quoin Pharmaceuticals bought some too, in the same month. It was the first purchase in over a year.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Quoin Pharmaceuticals over the 12 months to Nov 18, 2026: 4 clinical trials.
Insiders of Quoin Pharmaceuticals reported 17 open-market purchases and 1 sale since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $681K17×17 trades | $2171×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
4 active phase 3 trials and 0 active phase 2 trials led by this company, mostly in netherton syndrome. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last results
Nov 6, 2026
Within the 30 days after it, until Dec 6, 2026
Next results, expected
Not announced
Purchases after results
76%
13 of 17 insider purchases since 2023 came within 30 days after a results announcement
From Quoin Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Quoin Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Off-exchange trading: 33.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (7.1% on ATS, 26.5% with other brokers), below its 26-week average of 49.7%. Weeks of Sep 21 to Oct 16, 2026.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently either no approved or very limited treatments or cures. Our lead product, QRX003, is under clinical development as a potential treatment for Netherton Syndrome, a rare hereditary genetic disease. QRX003 is entering pivotal registrational clinical testing under an open IND application with the FDA. We have opened six clinical sites in the U.S. along with international sites that are being opened in the UK, Spain, France and the Netherlands. QRX003 is currently being tested in seven pediatric NS patients in investigator-initiated studies in Ireland, Austria, the Netherlands and New Zealand.
Largest ATS: UBS ATS (15.0%), SIGMA X2 (12.6%), CBX (11.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
And 10 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 26, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Records
Latest annual report filed Mar 26, 2026, compared with the one filed Mar 13, 2025. Read the filing
From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us.
Source: SEC EDGAR, Form 10-K filed Mar 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.